Durable anti-tumor response of nivolumab (anti-PD-1 antibody) for platinum-resistant ovarian cancer; phase II clinical trial with nivolumab

Hamanishi, Junzo

52
Durable anti-tumor response of nivolumab (anti-PD-1 antibody) for platinum-resistant ovarian cancer; phase II clinical trial with nivolumab

Tuesday, March 31, 2015: 8:16 AM

International Ballroom (Hilton Chicago)

J. Hamanishi¹, M. Mandai², N. Matsumura¹, K. Abiko¹, T. Baba¹, K. Yamaguchi¹ and I. Konishi¹
¹Kyoto University, Kyoto, Japan, ²Kinki University, Osakasayama, Japan

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

52
Durable anti-tumor response of nivolumab (anti-PD-1 antibody) for platinum-resistant ovarian cancer; phase II clinical trial with nivolumab

52 Durable anti-tumor response of nivolumab (anti-PD-1 antibody) for platinum-resistant ovarian cancer; phase II clinical trial with nivolumab

52
Durable anti-tumor response of nivolumab (anti-PD-1 antibody) for platinum-resistant ovarian cancer; phase II clinical trial with nivolumab